NEW YORK (GenomeWeb) – Adaptive Biotechnologies said today that it has agreed to use its technology to measure the efficacy of Janssen's Darzalex (daratumumab) in multiple myeloma (MM).

Under the terms of the collaboration, Adaptive will use its NGS-based ClonoSeq assay to measure minimal residual disease (MRD) in MM patients treated with Darzalex in ongoing clinical trials. The two companies hope to demonstrate the clinical utility of monitoring MRD as a way of assessing the medication's effectiveness.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.